Amylyx Pharmaceuticals Inc (AMLX)
6.71
+0.17
(+2.60%)
USD |
NASDAQ |
Nov 08, 16:00
6.95
+0.24
(+3.58%)
After-Hours: 20:00
Amylyx Pharmaceuticals Research and Development Expense (Quarterly): 21.24M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 21.24M |
| June 30, 2024 | 23.35M |
| March 31, 2024 | 36.61M |
| December 31, 2023 | 44.91M |
| September 30, 2023 | 30.04M |
| June 30, 2023 | 29.04M |
| March 31, 2023 | 24.19M |
| December 31, 2022 | 22.81M |
| Date | Value |
|---|---|
| September 30, 2022 | 24.91M |
| June 30, 2022 | 24.26M |
| March 31, 2022 | 21.46M |
| December 31, 2021 | 13.39M |
| September 30, 2021 | 12.85M |
| June 30, 2021 | 10.93M |
| March 31, 2021 | 6.864M |
| December 31, 2020 | 5.013M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.013M
Minimum
Dec 2020
44.91M
Maximum
Dec 2023
21.99M
Average
23.08M
Median
Research and Development Expense (Quarterly) Benchmarks
| PTC Therapeutics Inc | 161.41M |
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |
| Theriva Biologics Inc | 2.953M |